摘要:
The invention relates to a tuneable bisconjugate comprising two saccharides and a spacer, each saccharide being the same or different and comprising two to six monosaccharide units, at least one unit being uronic acid, characterized in that at least one of the saccharides per se has anti-thrombotic activity, and that the spacer connects at least one saccharide to the other through its non-reducing end, the chain length of the spacer being 20-120 atoms.
摘要:
The invention relates to sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type, of which N-sulfate, N-acetate, and hydroxy groups, are replaced by alkoxy, aryloxy, aralkoxy, or O-sulfate groups. The compounds have antithrombotic and smooth muscle cell proliferation inhibiting activities.
摘要:
The invention relates to 3-deoxy oligosaccharides of formula I: ##STR1## in which X represents an --OSO.sub.3.sup.- radical, a radical of formula R--O, a radical of formula: ##STR2## or a radical of formula: ##STR3## Y represents a radical of formula: ##STR4## R represents an alkyl radical, R.sub.1, R.sub.3, R.sub.5, R.sub.7, R.sub.8, R.sub.10, R.sub.12 and R.sub.13 represent a hydroxyl radical, an alkoxy radical or an --OSO.sub.3.sup.- radical,R.sub.2, R.sub.4, R.sub.6, R.sub.9 and R.sub.11 represent a hydrogen atom, a hydroxyl radical, an alkoxy radical or an --OSO.sub.3.sup.- radical, with the proviso that at least R.sub.2 or R.sub.4 or R.sub.6 or R.sub.9 or R.sub.11 represents a hydrogen atom,and their pharmaceutically acceptable salts with a base.
摘要:
Process for splitting off .DELTA..sup.4 -unsaturated uronic acid from glycosaminoglycan, in which the glycosaminoglycan is treated with an iodine solution or with a bleaching reagent, or with a combination thereof.
摘要:
The invention relates to new phosphorylating agents, a process for producing said compounds and their use in a process for the phosphorylation of organic hydroxyl compounds to obtain intermediate products useful for the production of polynucleotides. The phosphorylation is achieved without side reactions at the purine- or pyrimidine bases.